Eli Lilly and Company has announced plans to build a new $6.5-billion small-molecule active pharmaceutical product (API) manufacturing facility at Generation Park in Houston, Texas.  

The planned synthetic medicine API facility, the second of four new US sites Lilly is announcing in 2025, will focus on manufacturing the company’s pipeline of small-molecule medicines across multiple therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. The facility is expected to be operational within five years (as reported on September 23, 2025).  

This is the second location announced by Lilly following its announcement in February (February 2025) of its plans to bolster its US-based domestic medicine production by building four new pharmaceutical manufacturing sites in the United States. Earlier this month (September 2025), the company announced plans to build a $5-billion manufacturing facility just west of Richmond, Virginia. The new site in Virginia will be the company’s first dedicated, fully integrated API and drug product facility for Lilly’s emerging bioconjugate platform and monoclonal antibody portfolio, and the site will also boost its domestic manufacturing of antibody-drug conjugates. Lilly says it plans to announce later this year (2025) the two remaining locations for its other two planned facilities in the US. 

The Houston site will be among those that will manufacture orforglipron, Lilly’s first oral, small-molecule GLP-1 receptor agonist, which the company expects to submit to global regulatory agencies for obesity by the end of this year (2025). Lilly says its new site in Texas will bring 615 new jobs to the greater Houston area. The company also expects to generate 4,000 construction jobs as the site is being built and brought online. 

Lilly says it selected Generation Park, a commercial development in the Lake Houston area northeast of the city, from more than 300 applications based on criteria, including workforce potential, local incentives, access to utilities and transportation, and a favorable business environment.  

Source: Eli Lilly and Company